text:
Action Galore from the Hobbs and Shaw Movie -- Fast and Furious Presents Hobbs and Shaw Movie Review by Ms. H
Written by RealMsH
Disclaimer: The views expressed here are mine alone and do not represent those of allgames.com.
Introduction to Fast and Furious Presents Hobbs and Shaw Movie Review by Ms. H
Actors Dwayne Johnson (The Rock) and Jason Statham star in the movie Fast and Furious Presents Hobbs and Shaw. There were other noteworthy actors in this movie as well including a surprise one that drew a splattering of applause from the audience when he appeared.
Was this film exactly what I expected? Were there surprises and most importantly -- would I classify it as a "good" movie? Check out my movie review to find out.
Plot of Fast and Furious Presents Hobbs and Shaw Movie
In my opinion, the plot seemed like it was straight out of a comic book which revolved around a virus that has the potential to destroy the world. Sounds familiar? Of course this plot has been visited and revisited many times before in movies, tv shows, etc., so there was nothing really new here.
One of the subplots dealt with a villain trying to get the virus at all costs to use for wrong doings. In the midst of all of this, there is quite a bit of animosity (at least in the beginning) between Dwayne Johnson's character Hobbs and Jason Statham's character, Shaw.
Twists in the Fast and Furious Presents Hobbs and Shaw Movie
This movie is not one of those films where there is a huge revelation unbeknownst to the audience. Initially, you may be surprised of a sibling relationship in the movie. However, for the most part, it appears that the writer and director concentrated on the action scenes as well as the sometimes extraordinary stunt-type feats in the movie -- especially one dealing with a helicopter and trucks. If you watch the movie, you will know the scene I'm referring to.
Little known fact about the Fast and Furious Presents Hobbs and Shaw Movie: Jason Momoa (Aquaman) was the first choice to play the brother of Dwayne Wayne's character but was unable to do so according to sources because of his schedule.
Stand Out Actor in Fast and Furious Presents Hobbs and Shaw Movie
Even though all the actors performed adequately in their roles, I think that Idris Elba as the villain in this movie did an outstanding job. I do not recall that he ever played a villain, so I gave him even more kudos for doing an admirable job doing so.
Assessment of Fast and Furious Presents Hobbs and Shaw Movie
There were a few holes in the plot of this movie, which you may or may not notice. However, for action and entertainment value, I think this film did an adequate job. The strong points of the movie include the array of action scenes, as well as a hint of science fiction in the character played by Idris Alba. Some of the low points included the attempts at serious drama which in my opinion fell short.
To answer the question posed previously, I would categorize Fast and Furious Presents Hobbs and Shaw as an ok type movie which you may want to see if you are a fan of action films.
Rating of the Fast and Furious presents Hobbs and Shaw Movie
Based on a rating of 1 star to 5 stars, with 5 stars being the highest, I rate Fast and Furious Presents Hobbs and Shaw movie 3 ¼ stars.
Published in Mom's Minute Blog
Latest from RealMsH
Did the "Black Panther" Save 21 Bridges? 21 Bridges Movie Review by Ms. H
Are Predictable Movies Fun to Watch? The Good Liar Movie Review by Ms. H
A Race Car, Friendship Movie or Both? Ford v Ferrari Movie Review by Ms. H
What Worked and Didn't in Charlie's Angels 2019? Charlie's Angels 2019 Movie Review by Ms. H
Did the Midway Movie Deliver? Midway Movie Review by Ms. H
Now Playing: 28. Lon Lon Ranch


Is Zula Worth Playing In 2018?
Zula is a fast paced free to play shooter that's been out since November 2016. In Zula, players are divided into two factions. There's the paramilitary soldiers or the vigilantes, and matches involves a variety of maps and game modes to play through. Is Zula worth playing in 2018?
More important that any other aspect for FPS games is first and foremost the gunplay. Zula's shooting is incredibly speedy and spraying bullets and killing enemies happen almost at the speed of light. Players are trading the slower tactical combat feel of games like R6 for something that feels like Left 4 Dead. Is this a good thing? In most cases, especially as it lends a hectic and frantic atmosphere to the matches in-game.
Zula boasts over 150 weapons in the store, but the reality is it's less than that. The guns are standard and expect to see the usual suspects that are popular for each weapon category from Snipers, to Assault Rifles and SMGs. Players's progression involves earning XP for their profiles in addition to earning currency from matches. This can then be spent to unlock better guns which all have varying stats that make sense. Shotguns have higher recoil for example and does more damage but lacks accuracy. Popular systems for FPS today like customizing skins and accessories all are features in Zula, which players can spend premium currency for.
While the gameplay has the potential to engage players who prefer faster pace FPS, Zula falls short in other departments. For starters the maps are bland and uninspiring, with only 5 to choose from. The Ship is by far the best out of the lot, and even then it can get boring after a while. It gets slightly better with the game modes, and there are a few unorthodox modes like Hunt the Boss which totally devalues the PvP aspect, but fun nonetheless. Otherwise, it's easy to call this an imitation of any other successful FPS title.
Progression in many ways also carries that generic vibe. New players will spend quite a few hours trying to earn levels in order to upgrade weapons at level 10. From there on, things become quite the grind that's heighten by the repetitiveness of not having more than 5 maps.
From a graphics perspective, I think most players won't mind the aesthetics, but unfortunately they do feel dated and doesn't feel like a game that's made in 2016. Even on the High settings, textures are weak and the character models used both in the pre-match lobby and in-game are quite underwhelming. The good news is, it will probably run on very low-spec setting PCs, so at least it's accessible and free which could be important to some players.
Overall, Zula offers some fun here and there when it's prime time. If and when lobbies get filled with players, finding and playing matches for XP, badges and completing missions for boosts are all fun for the first few hours. After that, one may find that there are better offerings elsewhere.


Recorded in Nashville, Tennessee, in 1959.
Skeeters heart was set on singing three-part harmony and doing all the vocal parts herself, as well as being top country singer. Now the three-part harmony songs have the famous Skeeter Davis stamp, as observed in this album of answer songs, which contains six songs made famous artists Jim Reeves, Eddy Arnold, Ray Peterson, Don Gibson, Floyd Cramer and Hank Locklin.
"Country's never been afraid to lay on the corn, but even by its own standards, the concept driving this 1960 album was hokey. Davis sings "answer" songs to hits by Jim Reeves, Hank Locklin, Eddy Arnold, Jim Reeves, and Ray Peterson -- "I Really Want You to Know," for instance, in response to Arnold's "I Really Don't Want to Know." As all of those singers happened to be contracted to Davis' label, RCA, the original versions were available for inclusion/instant comparison. That means that half of this album isn't Davis at all; you'll hear, for instance, Jim Reeves singing "He'll Have to Go," followed immediately by Davis' "He'll Have to Stay"; Ray Peterson's "Tell Laura I Love Her" is countered with Davis' "Tell Tommy I Miss Him"; and so on. It gets really ridiculous when Davis sings an answer song ("My Last Date") to Floyd Cramer's instrumental hit "Last Date." Davis' songs are okay mainstream country/pop; a couple of them ("(I Can't Help You) I'm Falling Too" and "My Last Date") were even Top 40 pop hits. But alternating her tracks bang-bang with hits by various other male country stars makes for a rather herky-jerky listening experience [...]"


text:
Identification and treatment of T2-low asthma in the era of biologics
Chris Kyriakopoulos, Athena Gogali, Konstantinos Bartziokas, Konstantinos Kostikas
Chris Kyriakopoulos
Respiratory Medicine Dept, University of Ioannina School of Medicine, Ioannina, Greece
ORCID record for Chris Kyriakopoulos
Athena Gogali
Konstantinos Bartziokas
ORCID record for Konstantinos Bartziokas
Konstantinos Kostikas
ORCID record for Konstantinos Kostikas
For correspondence: ktkostikas@gmail.com
Currently, and based on the development of relevant biologic therapies, T2-high is the most well-defined endotype of asthma. Although much progress has been made in elucidating T2-high inflammation pathways, no specific clinically applicable biomarkers for T2-low asthma have been identified. The therapeutic approach of T2-low asthma is a problem urgently needing resolution, firstly because these patients have poor response to steroids, and secondly because they are not candidates for the newer targeted biologic agents. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and endotyping of T2-low asthma.
Ongoing investigation is focusing on neutrophilic airway inflammation mediators as therapeutic targets, including interleukin (IL)-8, IL-17, IL-1, IL-6, IL-23 and tumour necrosis factor-α; molecules that target restoration of corticosteroid sensitivity, mainly mitogen-activated protein kinase inhibitors, tyrosine kinase inhibitors and phosphatidylinositol 3-kinase inhibitors; phosphodiesterase (PDE)3 inhibitors that act as bronchodilators and PDE4 inhibitors that have an anti-inflammatory effect; and airway smooth muscle mass attenuation therapies, mainly for patients with paucigranulocytic inflammation.
This article aims to review the evidence for noneosinophilic inflammation being a target for therapy in asthma; discuss current and potential future therapeutic approaches, such as novel molecules and biologic agents; and assess clinical trials of licensed drugs in the treatment of T2-low asthma.
Th2-low endotype of asthma occurs in 50% of asthma patients. Novel targeted treatment with biologic agents is not currently approved. Nevertheless, other therapeutic options exist. Licensed drugs, novel molecules and biologics agents are under development. https://bit.ly/3bW7G0Q
Asthma is a chronic inflammatory disorder of the airways, characterised by reversible expiratory flow limitation and bronchial hyperresponsiveness (an increased sensitivity of the airways resulting in bronchoconstriction) to a variety of triggers. It presents with symptoms such as wheezing, shortness of breath, cough and chest tightness that vary over time and in severity [1]. This is a rough description, as asthma is not a homogenous disease in terms of disease natural history, severity and response to treatment. It has variable clinical presentations (phenotypes) and distinct underlying pathophysiological pathways (endotypes) responsible for this heterogeneity [2]. Based on the presence of T-helper cell type 2 (Th2)-driven inflammatory responses (interleukin (IL)-4-, IL-5- and IL-13-mediated), two major asthma endotypes, Th2 and non-Th2, have been described. The recent discovery of type-2 innate lymphoid cells and the fact that they can release Th-2 cytokines (predominantly IL-5 and IL-13), contributing to the type 2 (T2)-high signature, led to the better categorisation of asthma into T2-high or T2-low or non-T2. Currently, based on the existence of T2 biomarkers and the development of relevant biologic therapies, T2-high asthma is the most well-defined endotype [3]. T2-low asthma presents with either neutrophilic or paucigranulocytic inflammation, tends to be more resistant to inhaled corticosteroids, and it involves various asthma phenotypes, related to obesity, smoking, late onset (usually after the age of 40 years) or occupational exposures [2]. Thus, there is an unmet need for the identification of biomarkers that can help the diagnosis and the endotyping of T2-low asthma. The therapeutic approach of T2-low asthma is a problem urgently needing resolution for two main reasons: first, these patients have poor response to steroids, the cornerstone of asthma treatment [4], and second, they are not candidates for the newer targeted treatment with biologic agents such as anti-IgE or anti-IL-5 [5]. This review aims to discuss older as well as more recent therapeutic approaches, such as novel small molecules and biologic agents, in the treatment of T2-low asthma.
Definition of T2-low asthma
At present, a solid definition of T2-low asthma has not been established. Although some emphasis has been placed on noninvasive biomarkers for the detection of T2-high asthma (i.e. T2 cytokines such as IL-4, IL-5 and IL-13, exhaled nitric oxide fraction (FeNO), serum periostin, total IgE, blood and sputum eosinophils), the exact cut-off points for these markers are debatable [6]. Furthermore, these T2 markers may have low concordance when measured in the same patient [7, 8] and may be subject to significant variability over time and in response to asthma treatments [9]. The most important characteristic of these biomarkers is that they are characterised by high specificity, but low sensitivity, rendering them more useful in the identification of T2-high patients. In clinical practice, the most useful tool to identify T2-low asthma phenotype is the absence of any evidence of increased values in the aforementioned biomarkers of T2-high asthma. Additionally, it seems that there is an association of T2-low asthma with obesity, smoking, pollutants, viral or bacterial infections and advanced age. In terms of pathophysiology, T2-low asthma is usually characterised by neutrophilic (NA) or the paucigranulocytic (PGA; absence of sputum eosinophilia or neutrophilia) phenotype of inflammation [10] and Th1 and/or Th17 cells seem to be the key effector cells in this setting.
Several studies have related asthma severity to airway inflammation. Duong-Quy [11] has related eosinophilic inflammation to asthma management, asthma control and to predicting response to inhaled corticosteroids (ICS), through FeNO measurement. Kuo et al. [12] have shown that type 2 inflammation, as reflected by FeNO, serum immunoglobulin (Ig)E and blood eosinophils, plays a central role in small airways dysfunction in adults with moderate to severe persistent asthma. Louis et al. [13] demonstrated the connection between clinical activity, bronchial hyperresponsiveness and lung function to eosinophilic, and to a lesser degree, neutrophilic inflammation. In a recent study Scioscia et al. [14] showed a positive correlation between 17β-estradiol concentrations and neutrophil levels in in the sputum of female patients with postmenopausal severe asthma, and their results confirmed the central role of neutrophils in the pathogenesis of some forms of severe late-onset asthma. It is possible that increased airway remodelling is an important future risk factor for asthma, inducing further decline in pulmonary function, increased BHR, and exacerbation rate [15].
Neutrophilic phenotype
The percentage of neutrophils in the sputum of healthy controls ranges from 0% to 64% [16, 17], the aetiology of which may be shear stress in the mucosa during the induction process, the influence of specific resident microbiota or prior exposures to environmental agents. Airway neutrophilia may be associated with pollution [18], smoking [19], workplace agents [20], acute infections [21], chronic airway infections (e.g. in bronchiectasis) [22] or with an altered airway microbiome [23]. NA is common in smokers with asthma [19], obese asthmatics [24] and occupational asthma [25, 26]. The NA phenotype is characterised by a neutrophilic proportion of ≥64% in induced sputum [27, 28], although different cut-off values have been used in different studies ranging from 40% to 76% [29]. It is uncertain which cut-off value correlates with activated neutrophils promoting the pathogenic process [30]; nevertheless, sputum neutrophil counts have been associated with disease severity [31]. It is prudent to mention that sputum total cell count >15×106 cells·g−1 with a neutrophil percentage >64% is a strong indication of lower airway tract infection [32].
The NA phenotype accounts for 5–22% of asthmatic patients [33], often related to more severe disease with worse pulmonary function and poor asthma control [13]. Patients with NA are less responsive to ICS [34]; however, it is unclear if this corticosteroid insensitivity is related to the presence of neutrophils or if it is induced by the mechanisms underlying neutrophil recruitment [35].
Although blood eosinophils correlate with sputum eosinophilia, this is not applicable in the NA phenotype, in which blood neutrophilia cannot predict airway neutrophilia [30]. However, there are several candidate biomarkers to define NA, apart from the differential sputum cell counts; they are not applicable in clinical daily practice. Several cytokines are associated with neutrophilic airway inflammation. IL-6 is a pleiotropic cytokine produced by various cell types in response to a wide range of inflammatory stimuli. It is considered an indicator of metabolic dysfunction as well as asthma severity and has been identified as a potential candidate biomarker in a study with obese asthmatic patients [36]. Increased levels of IL-8, which is known to activate neutrophils, have been observed in patients with NA [37] and were linked to sputum neutrophil counts [38]. Other important biomarkers of neutrophil induction are myeloperoxidase and neutrophil elastase which can be discovered in induced sputum samples [39]. Tumour necrosis factor (TNF)-α [40], IL-23 [41] and IL-17 [42] are also related to neutrophilic inflammation in asthma. Maes et al. [43] have suggested that certain micro-RNAs in sputum might be able to accurately identify neutrophilic airway inflammation, but most clinicians are unable to obtain satisfactory sputum samples from these patients. Transcriptomic analysis of airway samples in severe neutrophilic asthma found a strong upregulation of mucins, IL-17-inducible chemokines (CXCL1, CXCL2, CXCL3 and CSF-3) and the neutrophil chemoattractants CXCL8 (IL-8), CCL3 and Galectin-3 (LGALS3) [44]. NA is associated with airway colonisation by bacteria including Haemophilus influenzae [45] and Moraxella catarrhalis [46], which might induce Th17 responses [47]. In addition, neutrophilic asthma is associated with upregulation of oxidative stress responses and matrix metalloproteases [48], including matrix metalloprotease (MMP)-9, a type IV collagenase involved with CXCL8-induced neutrophilia [49]. MMPs are increased in airway samples from asthmatic smokers and in severe neutrophilic asthma and are implicated in tissue remodelling [50].
Paucigranulocytic phenotype
Asthmatic patients with both neutrophil levels <64% and eosinophil levels <2% are classified as having PGA [29]. The prevalence of this phenotype in asthmatic patients ranges from 17% to 48% in different studies [30, 37]. Although little is known about the PGA phenotype, in the majority of patients with PGA the absence of inflammatory cells is usually related to appropriate anti-inflammatory treatment that achieves adequate asthma control [30]. Even though PGA is related to better lung function, a substantial proportion of patients with PGA (21.7%) are characterised as having severe refractory asthma, and 14.8% of patients with PGA have an Asthma Control Test score <19, suggesting that only this subpopulation of PGA is not well controlled despite the absence of inflammatory cells in their sputum [38]. Surprisingly, patients with PGA with severe refractory asthma presented with higher levels of FeNO and sputum IL-13 and IL-8 compared with those with mild-to-moderate asthma [37, 41]. Animal models demonstrate that processes stimulating airway hyperresponsiveness and airway smooth muscle thickening occur independently from inflammation and are a consequence of a loss of negative homeostatic processes, advancing eventually to the pathogenesis of asthma in PGA phenotype [51].
The main clinical and pathophysiological characteristics that can help distinguish T2-low from T2-high asthma are shown in table 1, while possible pathogenetic pathways, current drug targets and those in the development pipeline are shown in figure 1.
Differential diagnostic characteristics of type 2 (T2)-low versus T2-high asthma
Type 2-low asthma pathways and potential therapeutic targets. MMP: matrix metalloprotease; LTB: leukotriene B; IL: interleukin; Th: T-helper cell; INF: interferon; TNF: tumour necrosis factor; ILC: innate lymphoid cells.
Current therapeutic options
Presently, there are no specific therapeutic interventions for patients with PGA. A crucial and low-cost, but often overlooked, intervention that may dramatically improve asthma control in patients with NA is smoking cessation and avoidance of exposure to environmental/occupational pollutant agents. In smokers with NA, smoking cessation and avoidance of second-hand smoke resulted in the reduction of neutrophilic inflammation and improved asthma control and lung function [52].
Other treatment approaches currently available for T2-low asthma address noninflammatory pathways possibly involved in its pathogenesis. Tiotropium has been recently included as a new add-on treatment for Global Initiative for Asthma steps 4 and 5 in patients aged ≥18 years with a history of exacerbations. Its clinical efficacy has been demonstrated in patients with fixed airway obstruction, an asthma phenotype usually associated with neutrophilic airway inflammation [53] and in patients with low sputum eosinophils (and possibly T2-low asthma) [54].
Macrolides are often administered in refractory NA, although these antibiotics promote an enhanced risk of adverse events and promote bacterial resistance [55]. Macrolides exhibit their beneficial effects in NA with three mechanisms: 1) they exert antibacterial [56] and antiviral actions [57]; 2) they demonstrate immunomodulatory effects and anti-inflammatory activity through inhibition of transcription factors such as NFκB, reduction of activation and migration of neutrophils [58], revitalisation of corticosteroid sensitivity by inhibiting the phosphatidylinositol 3-kinase (PI3K) pathway and restoring histone deacetylase-2 [59] and by attenuating TNF-α and IL-17 immune responses [58]; and 3) they display prokinetic properties, thus diminishing the pernicious consequences of reflux and aspiration events [60]. Although not explicitly highlighted, macrolides reduce the sequence of reflux effects that include micro and macro aspiration of gastric contents, bronchoconstriction mediated by vagal reflexes [61] and neurogenic inflammation in the lung [62]. Erythromycin has been shown to promote gastric and small-bowel motility [63], increase lower oesophagal sphincter pressure [64] and affect gallbladder function [65]. Additionally, azithromycin exhibits action as a motilin receptor agonist [66] and enhances gastric motility in healthy subjects [67]. In patients with impaired gastrointestinal motility, azithromycin has shown comparable positive effects on gastric and duodenal motility to erythromycin [66]. In one study which included smoking asthmatics, the use of azithromycin did not induce amelioration of asthma control or lung function [68]. In other reports, azithromycin significantly improved asthma exacerbations and quality of life in both eosinophilic and noneosinophilic asthma [69, 70]. Moreover, the use of clarithromycin in patients with NA resulted in the reduction of neutrophilic inflammation followed by improvement in asthma control [71]. In a large randomised, double-blind study in moderate-to-severe asthma in Australia (AMAZES), azithromycin reduced exacerbations and improved Asthma Quality of Life Questionnaire scores [70]. Moreover, current European Respiratory Society/American Thoracic Society severe asthma guidelines recommend the use of azithromycin in severe asthma that does not respond to treatment [72].
Bronchial thermoplasty could be a possible therapeutic approach, but its long-term effectiveness or adverse events have not been fully assessed in PGA [73]. Bronchial thermoplasty administers targeted thermal energy to the airway wall, ablating airway smooth muscle (ASM) cells with a subsequent decrease in the ASM mass [74], while it has been verified that thermoplasty also regulates mucosal inflammatory responses and collagen deposition [75]. This intervention has been observed to reduce asthma exacerbations and to improve lung function and health-related quality of life. Moreover, macrolides may be an effective option in PGA, since the potential effects of azithromycin have been observed irrespective of the underlying airway inflammation [69].
The use of statins in clinical trials demonstrated alterations in several inflammatory markers, but failed to show improvement in asthma control or lung function [76].
Given the high prevalence of obesity in patients with T2-low asthma, weight reduction along with exercise and dietary modification should be included in the therapeutic plan of those patients. Several clinical studies have shown that weight loss in obese patients not only improves asthma symptoms, but also contributes to a reduction in doses of rescue medication. It also reduces the risk for severe asthma exacerbations and improves asthma-related quality of life, perhaps through improvements in lung function [77–79].
Future therapeutic targets
Although no specific treatments have been made available so far, according to the pathophysiology of T2-low asthma, some potential targets for therapeutic interventions are summarised herein [80]. An overview of the major biologic approaches currently in development for T2-low asthma management is shown in table 2.
Overview of the major biologic approaches currently in development for type 2 low asthma management
CXCR2/IL-8
IL-8 is a potent chemoattractant that regulates activation and migration of neutrophils to the site of inflammation through the high-affinity CXCR2 receptor. Increased levels of IL-8 in sputum often precede asthma exacerbations in severe asthmatics and coincide with the development of late-phase airflow obstruction in patients with atopy [97]. IL-8 is also elevated in the serum of those patients, but its role as a biomarker demonstrating disease activity remains disputable. CXCR2 is a common chemokine receptor, which is expressed on the surface of neutrophils. The tripeptide PGP, which is generated from extracellular matrix proteins through the action of matrix metalloproteinases, is also a neutrophil chemoattractant (matrikine) that activates CXCR2 [98]. These chemokines also attract circulating monocytes, which differentiate within the lung to macrophages that are thought to guide neutrophilic inflammation [99]. This implicates that blocking CXCR2 could be a tempting therapeutic approach to the treatment of neutrophilic inflammation since small molecule inhibitors to these G-protein receptors have now been developed.
In a phase 2 study of patients with moderate-to-severe asthma with high neutrophils count at baseline (>40%), CXCR2 antagonist SCH527123/navarixin demonstrated a significant reduction in sputum neutrophils by 36.3% compared to a 6.7% increase in the placebo group (p=0.03), but no significant improvement of asthma control was established and no change to forced expiratory volume in 1 s (FEV1) was proved [81, 82]. In a subsequent randomised clinical trial, using a CXCR2 antagonist (AZD5069) as add on therapy for patients with severe asthma 45 mg twice daily (n=161) for up 12 months resulted in a sustained ∼25% reduction in blood neutrophils, reversible on discontinuation of treatment. In severe asthmatics, 5, 15 or 45 mg twice daily for 6 months neither reduced the rate of exacerbations nor improved FEV1 or total asthma symptom score. A statistically significant reduction of sputum neutrophils by 69% was found in bronchiectasis patients after 80 mg twice daily for 4 weeks. There was no consistent increase in the rate of infections [82]. Another phase 1 clinical trial treatment of AZD8309, a CXCR2 antagonist, demonstrated a mean 77% reduction in total sputum cells (p<0.001) and 79% reduction in sputum neutrophils (p<0.05) compared with placebo after lipopolysaccharide (LPS) challenge. In addition, there was a reduction in neutrophil elastase activity (p<0.05) and CXCL1 (p<0.05) and trends for a reduction in sputum macrophages (47%), leukotriene B4 (39%) and CXCL8 (52%). The clinical trial was discontinued for asthma [83]. Overall, although CXCR2 antagonists seemed to be promising molecules as an add-on therapy for severe uncontrolled NA, they were not able to improve clinical outcomes and exacerbation rates [81–83].
IL-17
IL-17A and IL-17F are produced by Th17 cells and trigger the production of IL-8 and CXCL1 from epithelial cells. Moreover, they are neutrophil chemoattractants [100], while Th1 cells are connected to neutrophilic inflammation, by producing interferon-γ and TNF-α. Neutrophilic inflammation generated by this pathway leads to airway injury and remodelling, hyperplasia and hypersecretion of the mucus gland and corticosteroid insensitivity [76]. It has been recorded that severe NA is related to higher levels of Th17 cytokines, primarily CXCL1, CXCL10, CCl-2, IL-6 and IL-8 in comparison to other inflammatory endotypes [101]. In patients with asthma, elevated levels of IL-17A and IL-17F are found in bronchoalveolar lavage (BAL) and airway tissue biopsies and positively correlate with the level of disease severity and neutrophil inflammation [102]. Furthermore, IL-17A acts on airway smooth muscle cells and mediates airway hyperresponsiveness. IL-17A and IL17F bind to receptor complexes, with IL-17RA serving as the common subunit. Nevertheless, a recent study with mice models suggested that IL-17F, rather than IL-17A, underlies airway inflammation in steroid-insensitive asthma [103].
Secukinumab, an IL-17A blocker, administration in healthy volunteers who evolved acute neutrophilic airway inflammation following an ozone challenge did not demonstrate a significant change in the total number of sputum neutrophils from baseline. In a subsequent phase 2 study of AIN457 (secukinumab) in patients with uncontrolled asthma, there was no difference in Asthma Control Questionnaire (ACQ) score leading to its termination [104]. Brodalumab is a human monoclonal antibody that blocks the activity of IL-17A, IL-17B and IL-25 through binding to IL-17RA. In a randomised controlled trial recruiting patients with uncontrolled moderate-to-severe asthma on inhaled corticosteroids, brodalumab failed to show a change in ACQ score, asthma symptoms or lung function in the overall study population. However, it did show a trend towards improvement in ACQ score in a small subgroup of patients with high bronchodilator reversibility [84]. However, this drug led to significant mental health issues in clinical trials, thus resulting in discontinuation of further development for asthma. Another formulation of secukinumab (CJM112), an anti-IL17A antibody, is now in phase 2 randomised clinical trial for patients with inadequately controlled moderate-to-severe asthma with low IgE and low circulating eosinophil levels, but no results have been announced yet [105].
Most phosphodiesterase (PDE) isoenzymes are expressed in lung tissue, including PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE8 and PDE9; however, PDE3 and PDE4 have been the primary targets for drug therapy. The PDE4 isoenzyme is found in most inflammatory and immune cells, including T-cells, eosinophils, neutrophils, B-cells, monocytes, macrophages and dendritic cells. In several pre-clinical studies, PDE4 inhibitors have been shown to suppress bronchial hyperresponsiveness, eosinophil infiltration and production of histamine, leukotrienes and cytokines; however, they have significant side-effects when administered orally. PDE3 inhibitors act as bronchodilators, while PDE4 inhibitors have an anti-inflammatory effect [106]. PRL-554, an inhaled PDE3/4 inhibitor is now in a phase 1 trial for severe asthma. It is an analogue of trequinsin and, like trequinsin, is a highly selective inhibitor of the phosphodiesterase enzyme, PDE3. Indeed, it is >3000 times more potent against PDE3 than against PDE4. Ensifentrine (RPL554), a nebulised PDE3/4 inhibitor, demonstrated a significant dose-dependent bronchodilator response in asthma patients [76, 85, 86]. CHF6001, an inhaled PDE4 inhibitor, was evaluated in a phase 2 trial; the drug was safe and well tolerated at daily doses up to 4800 µg for 14 days in healthy volunteers. No results have been announced yet about drug efficacy [107].
TNF-α
TNF-α is secreted by lymphocytes, mast cells and macrophages and promotes bronchial hyperresponsiveness and sputum neutrophilia, thus was considered as an attractive target for severe asthma [87]. Etanercept (anti-TNF-α) showed short-term and modest clinical efficacy for severe and mild asthma, respectively [88]. Mild reduction in the number of exacerbations and improvement in wheezing was observed in patients with moderate uncontrolled asthma, who were under monotherapy with ICS, after administration of infliximab or adalimumab [108]. Golimumab lowered risk of asthma exacerbations; nevertheless, its trial on severe persistent asthma ended at phase 2 due to incidences of malignancies and infections such as pneumonia [87]. Given the possible beneficial role of TNF-α in severe NA, future studies may need to evaluate the long-term risk–benefit profile of these agents in such patients.
IL-1
IL-1β and IL-1 receptor antagonist genes have both been associated with asthma risk [109]. In humans, IL-1β is increased in BAL fluid and sputum of patients with asthma compared to normal volunteers [110], with airway macrophages from asthma patients also having increased expression of IL-1β [111]. In addition, IL-1β is increased in BAL fluid from persons with symptomatic asthma versus those with asymptomatic asthma [112], and there is an increased expression of this cytokine in the airway epithelium of asthmatics [112]. Furthermore, IL-1β appears to be involved in the recruitment of airway neutrophils by LPS in rat models [113] and is upregulated in the airway after LPS inhalation challenge in humans [114]. Canakinumab, a fully human immunoglobulin IgG1k monoclonal antibody against IL-1β, was originally developed as a potential treatment for asthma, but is no longer listed for that indication [115]. A study of anakinra, an IL-1β antagonist, in NA demonstrated a significant reduction of airway neutrophilia compared to placebo; subjects tolerated the treatment well, without an increased frequency of infections that have been attributable to anakinra [89].
IL-6 in sputum is associated with a lower FEV1 in patients with mixed eosinophilic–neutrophilic bronchitis [116]. In mice, allergen exposure increased lung IL-6, and IL-6 was produced by dendritic cells and alveolar macrophages. Loss of function of IL-6 signalling abrogated elevations of eosinophil and neutrophil recruiting cytokines/chemokines and allergen-induced airway inflammation in mice. The association of pleiotropic cellular airway inflammation with IL-6 using human and animal data suggests that exacerbations of asthma, particularly those with a combined eosinophilic and neutrophilic bronchitis, may respond to therapies targeting the IL-6 pathway [117]. Sirukumab, an IL-6 antagonist for patients having uncontrolled severe asthma despite the use of high-dose ICS in combination with long-acting β-agonist (LABA) is now in a phase 2a trial [118].
IL-22 and IL-23
Currently, one phase 2 ongoing clinical trial for anti-IL-23 monoclonal antibody (risankizumab) is attempting to investigate the efficacy and safety profile of this agent in T2-low severe asthmatic patients (clinicaltrials.gov identifier NCT02443298). There are no ongoing studies on IL-22 targeted therapy in asthma.
Several p38 mitogen-activated protein kinases (MAPK) inhibitors have shown to restore corticosteroid sensitivity in peripheral blood mononuclear cells from patients with severe asthma [119]. A phase 2 study of PF03715455 was conducted and was terminated due to business reasons, without any safety or efficacy concerns [120]. A post hoc analysis of a 6-month clinical trial with losmapimod (GW856553) in COPD, but not in asthma, reported a reduction in exacerbations in a subgroup of patients with a blood eosinophil count ≤2%, which may suggest a preferentially beneficial effect of p38 MAPK inhibitors in noneosinophilic inflammation [90]. In COPD, AZD7624, an inhaled p38α and p38β inhibitor, significantly reduced additional inflammatory biomarkers from sputum (IL-6, IL-8 and macrophage inflammatory protein (MIP)-1β) and blood (neutrophil percentage, IL-6, MIP-1β and C-reactive protein), but demonstrated no benefit concerning the reduction of exacerbations [91].
Inhibition of the stem cell factor/c-kit receptor pathway leads to a significant decrease of the mast cell population, histamine levels, IL-4 production and airway hyperresponsiveness. Growth factors such as platelet-derived growth factor (PDGF) contribute to bronchial remodelling, a characteristic of severe asthma [121]. Masitinib and imatinib are tyrosine kinase inhibitors, targeting stem cell factor receptor/c-kit and PDGF receptor. A phase 2a study of masitinib in severe, uncontrolled, corticosteroid-dependent asthmatics was conducted, showing no significant difference to the corticosteroid weaning process; in contrast, a significant improvement in asthma control was observed [92].
PI3K and Janus-activated kinases (JAK) modulate lymphocyte activation. JAK and PI3K inhibitors reduced the cytokine level through direct effects on T-cell activation in both asthma and healthy BAL cells. Nemiralisib (GSK2269557), a once-daily inhaled PI3Kδ inhibitor underwent a phase 2 clinical trial for patients with severe, uncontrolled asthma. It exhibited a significant reduction in sputum IL-5, IL-13, IL-6 and IL-8 level; however, it had no discernible difference in trough FEV1 and Asthma Control Test score [93]. PI3Kδ and γ isoforms are involved in inflammatory cell recruitment and activation and dual PI3Kδ/γ inhibitors, such as TG100–115 and IPI145 reduces airway inflammation induced by allergen or cigarette smoke in murine models [94, 95] and restored corticosteroid sensitivity in the smoke model [95]. A phase 2 study of RV1729, an inhaled PI3Kγ/δ inhibitor, demonstrated attenuation of airway inflammation, promotion of bronchodilation and reversal of β2-adrenoreceptor tachyphylaxis [96]. Both IPI-145 (duvelisib) and RV-1729 are PI3Kδ/PI3Kγ combination inhibitors that are being developed for clinical use [94, 95]. Furthermore, the combination of dexamethasone with either a JAK or PI3Kδ inhibitor showed an additive anti-inflammatory effect [122]. Recently, an inhaled inhibitor of JAK1 and intravenous administration of human mesenchymal stem cells attenuated neutrophilic inflammation in an experimental murine of allergic asthma [123]. Overall, the inhibition of PI3K blunts mucus production, prevents mast cell degranulation, deters immune cell recruitment and facilitates bronchodilation, all of which are potentially beneficial in asthma [124], but these need to be proven in future clinical trials.
Treating T2-low asthma is a therapeutic challenge, mainly because its mechanisms are not fully understood. Although much progress has been made in elucidating T2-high inflammation pathways, no specific biomarkers for T2-low asthma have been identified. Neutrophilic airway inflammation mediator targets, including IL-8, IL-17, IL-1, IL-6, IL-23, TNF-α or airway smooth muscle mass attenuation therapies (for paucigranulocytic inflammation) are under investigation. Failed previous attempts with some of the agents targeting these mechanisms may have been due to the poor characterisation of severe T2-low asthma. Further studies are necessary to accurately characterise T2-low pathogenetic processes to assess novel evidence-based treatments.
Conflict of interest: C. Kyriakopoulos has nothing to disclose.
Conflict of interest: A. Gogali has nothing to disclose.
Conflict of interest: K. Bartziokas has nothing to disclose.
Conflict of interest: K. Kostikas was an employee and shareholder of Novartis Pharma AG until 31 October 2018; he has received honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, ELPEN, GSK, Menarini, Novartis and Sanofi; his department has received funding and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Innovis, Menarini, Novartis and NuvoAir.
Copyright ©ERS 2021
Global Initiative for Asthma (GINA). 2019 Pocket Guide for Asthma Management: For Adults and Children Over 5 Years. Available from http://ginasthma.org/
Kuruvilla ME,
Lee FE-H,
Lee GB
. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 2019; 56: 219–233. doi:10.1007/s12016-018-8712-1
van Rijt L,
von Richthofen H,
van Ree R
. Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. Semin Immunopathol 2016; 38: 483–496. doi:10.1007/s00281-016-0556-2
Gaga M,
Zervas E,
Samitas K, et al.
Severe asthma in adults. Clin Chest Med 2012; 33: 571–583. doi:10.1016/j.ccm.2012.06.008
Holguin F,
Cardet JC,
Chung KF, et al.
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2020; 55: 1900588. doi:10.1183/13993003.00588-2019
Shah SP,
Grunwell J,
Shih J, et al.
Exploring the utility of noninvasive type 2 inflammatory markers for prediction of severe asthma exacerbations in children and adolescents. J Allergy Clin Immunol Pract 2019; 7: 2624–2633. doi:10.1016/j.jaip.2019.04.043
Hastie AT,
Moore WC,
Li H, et al.
Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013; 132: 72–80. doi:10.1016/j.jaci.2013.03.044
Haughney J,
Morice A,
Blyth KG, et al.
A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med 2018; 134: 117–123. doi:10.1016/j.rmed.2017.12.001
Mathur SK,
Fichtinger PS,
Evans MD, et al.
Variability of blood eosinophil count as an asthma biomarker. Ann Allergy Asthma Immunol 2016; 117: 551–553. doi:10.1016/j.anai.2016.08.010
Papaioannou AI,
Diamant Z,
Bakakos P, et al.
Towards precision medicine in severe asthma: treatment algorithms based on treatable traits. Respir Med 2018; 142: 15–22. doi:10.1016/j.rmed.2018.07.006
Duong-Quy S
. Clinical utility of the exhaled nitric oxide (NO) measurement with portable devices in the management of allergic airway inflammation and asthma. J Asthma Allergy 2019; 12: 331–341. doi:10.2147/JAA.S190489
Kuo CR,
Jabbal S,
Lipworth B
. Is small airways dysfunction related to asthma control and type 2 inflammation? Ann Allergy Asthma Immunol 2018; 121: 631–632. doi:10.1016/j.anai.2018.08.009
Louis R,
Lau LCK,
Bron AO, et al.
The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161: 9–16. doi:10.1164/ajrccm.161.1.9802048
Wardzyńska A,
Pawełczyk M,
Rywaniak J, et al.
Circulating microRNAs and T-cell cytokine expression are associated with the characteristics of asthma exacerbation. Allergy Asthma Immunol Res 2020; 12: 125–136. doi:10.4168/aair.2020.12.1.125
Scioscia G,
Carpagnano GE,
Lacedonia D, et al.
The role of airways 17β-estradiol as a biomarker of severity in postmenopausal asthma: a pilot study. J Clin Med Res 2020; 9: 2037.
Wen Y,
Reid DW,
Zhang D, et al.
Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 327–334.
Pirogov AB,
Prikhod'ko AG,
Perelman YM, et al.
Inflammatory pattern of the bronchial mucosa in patients with asthma with airway hyperresponsiveness to hypoosmotic stimulus. Bull Exp Biol Med 2016; 161: 550–553. doi:10.1007/s10517-016-3458-3
Alexis NE,
Carlsten C
. Interplay of air pollution and asthma immunopathogenesis: a focused review of diesel exhaust and ozone. Int Immunopharmacol 2014; 23: 347–355. doi:10.1016/j.intimp.2014.08.009
Shimoda T,
Obase Y,
Kishikawa R, et al.
Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy Asthma Pro 2016; 37: 50–58. doi:10.2500/aap.2016.37.3944
Tarlo SM,
Lemiere C
. Occupational asthma. N Engl J Med 2014; 370: 640–649. doi:10.1056/NEJMra1301758
Yang X,
Jiang Y,
. Does IL-17 respond to the disordered lung microbiome and contribute to the neutrophilic phenotype in asthma? Mediators Inflamm 2016; 2016: 6470364.
Simpson JL,
Grissell TV,
Douwes J, et al.
Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007; 62: 211–218. doi:10.1136/thx.2006.061358
Green BJ,
Wiriyachaiporn S,
Grainge C, et al.
Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment-resistant severe asthma. PLoS One 2014; 9: e100645. doi:10.1371/journal.pone.0100645
Denlinger LC,
Phillips BR,
Ramratnam S, et al.
Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med 2017; 195: 302–313. doi:10.1164/rccm.201602-0419OC
Lemière C,
Boulet L-P,
Chaboillez S, et al.
Work-exacerbated asthma and occupational asthma: do they really differ? J Allergy Clin Immunol 2013; 131: 704–710. doi:10.1016/j.jaci.2012.08.024
Dominguez-Ortega J,
Barranco P,
Rodríguez-Pérez R, et al.
Biomarkers in occupational asthma. Curr Allergy Asthma Rep 2016; 16: 63. doi:10.1007/s11882-016-0644-3
Schleich FN,
Seidel L,
Sele J, et al.
Exhaled nitric oxide thresholds associated with a sputum eosinophil count ≥3% in a cohort of unselected patients with asthma. Thorax 2010; 65: 1039–1044. doi:10.1136/thx.2009.124925
Belda J,
Leigh R,
Parameswaran K, et al.
Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161: 475–478. doi:10.1164/ajrccm.161.2.9903097
Scott R,
Boyle MJ, et al.
Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54–61. doi:10.1111/j.1440-1843.2006.00784.x
Manise M,
Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11. doi:10.1186/1471-2466-13-11
Li X, et al.
Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133: 1557–1563. doi:10.1016/j.jaci.2013.10.011
Wang H,
Dasgupta A,
Lee K-A, et al.
Changing pattern of sputum cell counts during successive exacerbations of chronic obstructive pulmonary disease. COPD 2015; 12: 628–635.
Arron JR,
Choy DF,
Laviolette M, et al.
Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. Eur Respir J 2014; 43: 627–629. doi:10.1183/09031936.00117013
Berry M,
Morgan A,
Shaw DE, et al.
Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62: 1043–1049. doi:10.1136/thx.2006.073429
Nair P,
Aziz-Ur-Rehman A,
Radford K
. Therapeutic implications of 'neutrophilic asthma'. Curr Opin Pulm Med 2015; 21: 33–38. doi:10.1097/MCP.0000000000000120
Peters MC,
McGrath KW,
Hawkins GA, et al.
Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016; 4: 574–584. doi:10.1016/S2213-2600(16)30048-0
Ntontsi P,
Loukides S,
Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes. Allergy 2017; 72: 1761–1767. doi:10.1111/all.13184
Gibson PG,
Saltos N
. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329–1336. doi:10.1378/chest.119.5.1329
Jatakanon A,
Uasuf C,
Maziak W, et al.
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532–1539. doi:10.1164/ajrccm.160.5.9806170
Silvestri M,
Bontempelli M,
Giacomelli M, et al.
High serum levels of tumour necrosis factor-α and interleukin-8 in severe asthma: markers of systemic inflammation? Clin Exp Allergy 2006; 36: 1373–1381. doi:10.1111/j.1365-2222.2006.02502.x
Casale TB
. Biologics and biomarkers for asthma, urticaria, and nasal polyposis. J Allergy Clin Immunol 2017; 139: 1411–1421. doi:10.1016/j.jaci.2017.03.006
Al-Ramli W,
Préfontaine D,
Chouiali F, et al.
TH17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123: 1185–1187. doi:10.1016/j.jaci.2009.02.024
Maes T,
Cobos FA,
Schleich F, et al.
Asthma inflammatory phenotypes show differential microRNA expression in sputum. J Allergy Clin Immunol 2016; 137: 1433–1446. doi:10.1016/j.jaci.2016.02.018
Singhania A,
Wallington JC,
Smith CG, et al.
Multitissue transcriptomics delineates the diversity of airway T cell functions in asthma. Am J Respir Cell Mol Biol 2018; 58: 261–270. doi:10.1165/rcmb.2017-0162OC
Daly J,
Baines KJ, et al.
Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J 2016; 47: 792–800. doi:10.1183/13993003.00405-2015
De Schutter I,
Dreesman A,
Soetens O, et al.
In young children, persistent wheezing is associated with bronchial bacterial infection: a retrospective analysis. BMC Pediatr 2012; 12: 83. doi:10.1186/1471-2431-12-83
Hynes GM,
Hinks TSC
. The role of interleukin-17 in asthma: a protective response? ERJ Open Res 2020; 6: 00364–02019. doi:10.1183/23120541.00364-2019
Chaudhuri R,
McSharry C,
Brady J, et al.
Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to disease severity. J Allergy Clin Immunol 2012; 129: 655–663. doi:10.1016/j.jaci.2011.12.996
Mukhopadhyay S,
Sypek J,
Tavendale R, et al.
Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults. J Allergy Clin Immunol 2010; 126: 70–76. doi:10.1016/j.jaci.2010.03.027
Hunninghake GM,
Cho MH,
Tesfaigzi Y, et al.
MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599–2608. doi:10.1056/NEJMoa0904006
Cooper PR,
Mesaros AC,
Zhang J, et al.
20-HETE mediates ozone-induced, neutrophil-independent airway hyper-responsiveness in mice. PLoS One 2010; 5: e10235. doi:10.1371/journal.pone.0010235
Livingston E,
McMahon AD, et al.
Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 2006; 174: 127–133. doi:10.1164/rccm.200510-1589OC
Kerstjens HAM,
Disse B,
Schröder-Babo W, et al.
Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308–314. doi:10.1016/j.jaci.2011.04.039
Lazarus SC,
Krishnan JA,
King TS, et al.
Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med 2019; 380: 2009–2019. doi:10.1056/NEJMoa1814917
Cameron EJ,
Chaudhuri R, et al.
Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy 2012; 42: 1302–1312. doi:10.1111/j.1365-2222.2012.03979.x
Jelić D,
Antolović R
. From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. Antibiotics 2016; 5: 29. doi:10.3390/antibiotics5030029
Schögler A,
Kopf BS,
Edwards MR, et al.
Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45: 428–439. doi:10.1183/09031936.00102014
Kobayashi Y,
Wada H,
Rossios C, et al.
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013; 169: 1024–1034. doi:10.1111/bph.12187
Culić O,
Eraković V,
Parnham MJ
. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–229. doi:10.1016/S0014-2999(01)01321-8
Hahn DL
. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 2234–2237.
Amarasiri DL,
Pathmeswaran A,
de Silva HJ, et al.
Response of the airways and autonomic nervous system to acid perfusion of the esophagus in patients with asthma: a laboratory study. BMC Pulm Med 2013; 13: 33. doi:10.1186/1471-2466-13-33
Ribó P,
Pacheco A,
Arrieta P, et al.
Gastroesophageal reflux as a cause of chronic cough, severe asthma, and migratory pulmonary infiltrates. Respirol Case Rep 2014; 2: 1–3.
Tomomasa T,
Kuroume T,
Arai H, et al.
Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157–161. doi:10.1007/BF01300701
Pennathur A,
Cioppi M, et al.
Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. Am J Surg 1994; 167: 169–172. doi:10.1016/0002-9610(94)90069-8
Catnach SM,
Fairclough PD
. Erythromycin and the gut. Gut 1992; 33: 397–401. doi:10.1136/gut.33.3.397
Broad J,
Sanger GJ
. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 2013; 168: 1859–1867. doi:10.1111/bph.12077
Sifrim D,
Matsuo H,
Janssens J, et al.
Comparison of the effects of midecamycin acetate and azithromycin on gastrointestinal motility in man. Drugs Exp Clin Res 1994; 20: 121–126.
Essilfie A-T,
Horvat JC,
Kim RY, et al.
Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70: 458–467. doi:10.1136/thoraxjnl-2014-206067
Mair F, et al.
Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J 2013; 42: 1412–1415. doi:10.1183/09031936.00093913
Yang IA,
Upham JW, et al.
Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 659–668. doi:10.1016/S0140-6736(17)31281-3
Powell H,
Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148–155. doi:10.1164/rccm.200707-1134OC
Chung KF,
Wenzel SE,
Brozek JL, et al.
Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 44: 267–268. doi:10.1183/09031936.00064614
Ong KY
. What's new in the Global Initiative for Asthma 2018 report and beyond. Allergo J Int 2019; 28: 63–72. doi:10.1007/s40629-018-0079-6
Laxmanan B,
Egressy K,
Murgu SD, et al.
Advances in bronchial thermoplasty. Chest 2016; 150: 694–704. doi:10.1016/j.chest.2016.03.012
Schuhmann M,
Konietzke P,
Wielpütz M, et al.
Reduction of bronchial wall thickness and hyperinflation on quantitative CT after bronchial thermoplasty for severe asthma. Eur Respir J 2017; 50: PA3028. doi:10.1183/1393003.congress-2017.PA3028
Thomson NC
. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis 2016; 10: 211–234.
Ulrik CS
. Asthma and obesity: is weight reduction the key to achieve asthma control? Curr Opin Pulm Med 2016; 22: 69–73. doi:10.1097/MCP.0000000000000226
Adeniyi FB,
Young T
. Weight loss interventions for chronic asthma. Cochrane Database Syst Rev 2012; 7: CD009339.
Forno E,
Han Y-Y,
Mullen J, et al.
Overweight, obesity, and lung function in children and adults – a meta-analysis. J Allergy Clin Immunol Pract 2018; 6: 570–581. doi:10.1016/j.jaip.2017.07.010
Zhu L,
Ciaccio CE,
. Potential new targets for drug development in severe asthma. World Allergy Organ J 2018; 11: 30. doi:10.1186/s40413-018-0208-1
Zervas E, et al.
Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42: 1097–1103. doi:10.1111/j.1365-2222.2012.04014.x
O'Byrne PM,
Metev H,
Puu M, et al.
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4: 797–806. doi:10.1016/S2213-2600(16)30227-2
Leaker BR,
Barnes PJ,
O'Connor B
. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res 2013; 14: 137. doi:10.1186/1465-9921-14-137
Busse WW,
Holgate S,
Kerwin E, et al.
Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294–1302. doi:10.1164/rccm.201212-2318OC
Verona Pharma. Verona Pharma reports Positive Results From RPL554 Dose-Finding Study. www.veronapharma.com/media/verona-pharma-reports-positive-results-rpl554-dose-finding-study/ Date last updated: 15 March 2016.
Singh D,
Abbott-Banner K,
Bengtsson T, et al.
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD. Eur Respir J 2018; 52: 1801074. doi:10.1183/13993003.01074-2018
Bleecker ER, et al.
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549–558. doi:10.1164/rccm.200809-1512OC
Antoniu SA
. Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs 2009; 23: 241–251. doi:10.2165/11317130-000000000-00000
Hernandez ML,
Mills K,
Almond M, et al.
IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol 2015; 135: 379–385. doi:10.1016/j.jaci.2014.07.039
Marks-Konczalik J,
Costa M,
Robertson J, et al.
A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils. Respir Med 2015; 109: 860–869. doi:10.1016/j.rmed.2015.05.003
Patel NR,
Cunoosamy DM,
Fagerås M, et al.
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2018; 13: 1009–1019. doi:10.2147/COPD.S150576
Humbert M,
de Blay F,
Garcia G, et al.
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009; 64: 1194–1201. doi:10.1111/j.1398-9995.2009.02122.x
Khindri S,
Cahn A,
Begg M, et al.
A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma. J Pharmacol Exp Ther 2018; 367: 405–413. doi:10.1124/jpet.118.249516
Winkler DG,
Faia KL,
DiNitto JP, et al.
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20: 1364–1374. doi:10.1016/j.chembiol.2013.09.017
Doukas J,
Eide L,
Stebbins K, et al.
Aerosolized phosphoinositide 3-kinase γ/δ inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009; 328: 758–765. doi:10.1124/jpet.108.144311
Koziol-White CJ,
Zhang J,
Yoo E, et al.
A narrow spectrum kinase inhibitor, RV1729, induces bronchodilation of human small airways and rescues agonist-induced desensitization of the 2 adrenoreceptor (2AR). Am J Respir Crit Care Med 2016; 193: A6841.
Mukaida N
. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 2003; 284: L566–L577. doi:10.1152/ajplung.00233.2002
Jackson PL,
Tanner S, et al.
A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One 2011; 6: e15781. doi:10.1371/journal.pone.0015781
Traves SL,
Culpitt SV,
Russell REK, et al.
Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD. Thorax 2002; 57: 590–595. doi:10.1136/thorax.57.7.590
Sergejeva S,
Ivanov S,
Lötvall J, et al.
Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol 2005; 33: 248–253. doi:10.1165/rcmb.2004-0213OC
Fogli LK,
Sundrud MS,
Goel S, et al.
T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol 2013; 191: 3100–3111. doi:10.4049/jimmunol.1390058
Ricciardolo FLM,
Sorbello V,
Vallese D, et al.
Expression of nasal and bronchial IL-17F and related cytokines in frequent exacerbators with neutrophilic severe asthma. Eur Respir J 2016; 48: PA4176. doi:10.1183/13993003.congress-2016.PA4176
Chen R,
Zhang Q,
Chen S, et al.
IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model. Eur Respir J 2019; 53: 1801510. doi:10.1183/13993003.01510-2018
Zhang M,
Fei X,
Zhang G-Q, et al.
Role of neutralizing anti-murine interleukin-17A monoclonal antibody on chronic ozone-induced airway inflammation in mice. Biomed Pharmacother 2016; 83: 247–256. doi:10.1016/j.biopha.2016.06.041
Novartis Pharmaceuticals. Study to Assess the Efficacy and Safety of CJM112 in Patients with Inadequately Controlled Severe Asthma. https://clinicaltrials.gov/ct2/show/NCT03299686/ Date last updated: 12 August 2020.
Miller M
. Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential. J Recept Ligand Channel Res 2015; 8: 19–30. http://dx.doi.org/10.2147/jrlcr.s50401
Lucci G,
Mariotti F,
Santoro D, et al.
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers. Eur Respir J 2016; 48: PA4086.
Erin EM,
Nicholson GC, et al.
The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006; 174: 753–762. doi:10.1164/rccm.200601-072OC
He Y,
Peng S,
Xiong W, et al.
Association between polymorphism of interleukin-1 beta and interleukin-1 receptor antagonist gene and asthma risk: a meta-analysis. ScientificWorldJournal 2015; 2015: 685684.
Konno S,
Gonokami Y,
Kurokawa M, et al.
Cytokine concentrations in sputum of asthmatic patients. Int Arch Allergy Immunol 1996; 109: 73–78. doi:10.1159/000237234
Mazzarella G,
Grella E,
D'Auria D, et al.
Phenotypic features of alveolar monocytes/macrophages and IL-8 gene activation by IL-1 and TNF-alpha in asthmatic patients. Allergy 2000; 55: Suppl. 61, 36–41. doi:10.1034/j.1398-9995.2000.00505.x
Sousa AR,
Lane SJ,
Nakhosteen JA, et al.
Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am J Respir Crit Care Med 1996; 154: 1061–1066. doi:10.1164/ajrccm.154.4.8887608
Wagner JG,
Kala A, et al.
Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers. Free Radic Biol Med 2013; 60: 56–62. doi:10.1016/j.freeradbiomed.2013.02.001
Kim RY,
Pinkerton JW,
Essilfie AT, et al.
Role for NLRP3 inflammasome–mediated, IL-1β–dependent responses in severe, steroid-resistant asthma. Am J Respir Crit Care Med 2017; 196: 283–297. doi:10.1164/rccm.201609-1830OC
Church LD,
McDermott MF
. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Rev Clin Immunol 2010; 6: 831–841. doi:10.1586/eci.10.66
Chu DK,
Al-Garawi A,
Llop-Guevara A, et al.
Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy Asthma Clin Immunol 2015; 11: 14. doi:10.1186/s13223-015-0081-1
Banno A,
Reddy AT,
Lakshmi SP, et al.
PPARs: key regulators of airway inflammation and potential therapeutic targets in asthma. Nucl Receptor Res 2018; 5: 101306. doi:10.11131/2018/101306
GlaxoSmithKline. A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects with Severe Poorly Controlled Asthma. https://clinicaltrials.gov/ct2/show/NCT02794519/ Date last updated: 31 August 2018.
Lea S,
Harbron C,
Khan N, et al.
Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. Br J Clin Pharmacol 2015; 79: 756–766. doi:10.1111/bcp.12536
Pfizer. An Evaluation of PF-03715455 in Moderate to Severe Uncontrolled Asthma. https://clinicaltrials.gov/ct2/show/NCT02219048/ Date last updated: 12 June 2019.
Reber L,
Da Silva CA,
Frossard N
. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533: 327–340. doi:10.1016/j.ejphar.2005.12.067
Southworth T,
Plumb J,
Gupta V, et al.
Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients. Respir Res 2016; 17: 124. doi:10.1186/s12931-016-0436-2
Zhang L-B,
. Effect of mesenchymal stromal (stem) cell (MSC) transplantation in asthmatic animal models: a systematic review and meta-analysis. Pulm Pharmacol Ther 2019; 54: 39–52. doi:10.1016/j.pupt.2018.11.007
Yoo EJ,
Ojiaku CA,
Sunder K, et al.
Phosphoinositide 3-kinase in asthma: novel roles and therapeutic approaches. Am J Respir Cell Mol Biol 2017; 56: 700–707. doi:10.1165/rcmb.2016-0308TR
You are going to email the following Identification and treatment of T2-low asthma in the era of biologics
Pulmonary pharmacology and therapeutics
Home monitoring to detect ILD exacerbations and progression
Individual trajectory-based care for COPD
Lower airway clinical outcome measures for use in primary ciliary dyskinesia research: a scoping review

redpajama_set_name: RedPajamaCommonCrawl


To raise awareness of and enquiries for a new range of products whilst continuing to promote their core workholding solution business.
• In Q4 2015 achieved an average of 13.86k reach per month, 42 link clicks per month and 37.3 Twitter RTs from an average of just 2 social media interactions per day.
• Organically improved their SEO - they rose to the top of page 1 in Google for the UK term 'workholding'.


text:
A Picture of a Picture is een studioalbum van Aidan Baker samen met This Quiet Army. This Quiet Army bestaat slechts uit één man: Eric Quach. Zowel Baker als Quach speelt ambient-muziek van het lichte spectrum tot de zware industrial-tak. A Picture of a Picture bevat een mengeling van allerlei ambient, waarbij de kleuring dan weer licht en dan weer donker is; extreme uitingen komen echter niet voor. Het was de tweede samenwerking van de heren, ze hadden eerder een ep Orange uitgebracht in een oplage van 200 exemplaren, die binnen mum was uitverkocht. A Picture is gezamenlijk opgenomen in 2007 en is voor het overgrote deel live (direct op tape of pc) ingespeeld, later is er nog een beetje aan gesleuteld. Eindverantwoordelijk was Quach uit Montreal. Baker zal het te druk hebben gehad met andere werkzaamheden (in 2009 waren er zes albums van hem). Het album is op 29 juni 2010 uitverkocht bij platenlabel Killer Pimp; het is nog wel op iTunes de benaderen.

Musici
Aidan Baker, Eric Quach – gitaar

Tracklist

Muziekalbum uit 2009
Muziekalbum van Aidan Baker
Ambientalbum

redpajama_set_name: RedPajamaWikipedia


ojo recently sponsored the Civil Society's annual Charity Technology Conference, held in London last month. This unique event, designed for Charity IT & Digital leaders, showcased the best of innovation across the sector.
Having worked in the third sector for the last 15 years, Nathan gave a keynote speech surrounding the challenges he has faced in creating transformational change within the Disabilities Trust. As their Director of Technology, heading a programme to modernise and transform the business through the use of innovative IT solutions, Nathan's talk had many practical tips for charities to achieve their objectives.
With ojo also exhibiting at the conference, some superb conversations were had by the team with many third sector digital leaders.
This entry was posted in News and tagged Charity Technology Conference 2016, Glove Factory Studios, hollt, Holt Wiltshire, ojo solutions on December 13, 2016 by Tom Marshall.


text:
Las elecciones al Parlamento de Canarias de 1983 se celebraron el 8 de mayo. En ellas el PSOE fue el partido más votado, y tras llegar a un acuerdo con la Asamblea Majorera y con la Agrupación Herreña Independiente, su candidato, Jerónimo Saavedra, fue investido primer presidente regional electo de Canarias.

Resultados

Elección e investidura del Presidente de Canarias

Resultados por islas

El Hierro

La Palma

La Gomera

Tenerife

Gran Canaria

Fuerteventura

Lanzarote

Referencias

Enlaces externos
 Sistema de información electoral en Canarias

1983
Canarias


For the first time this year, 1,500 film lovers, aged from 18-28, have been invited to the Festival de Cannes. For three whole days (from 17 to 19 May), they will enjoy an opportunity to discover the 71st Festival and the films in the Official Selection.
What is "3 DAYS IN CANNES"?
A 3-day pass giving access to a dedicated programme from the Official Selection (Competition, Out of Competition, Special Screenings, Un Certain Regard, Cannes Classics, Cinéma de la plage) and to the Palais des Festivals.
In Cannes, on 17, 18, 19 May 2018 – a chance to experience the final 3 days of the event and enjoy the Festival on the Croisette. Badges can be collected from Wednesday 16 May 2018 at the Palais des Festivals.
When and where can I pick up my "3 DAYS IN CANNES" badge?
Which zone can I access with my "3 DAYS IN CANNES" badge?
With your badge, you will be able to access the Palais des festivals and its projection rooms, from Thursday 17 May until Saturday 18 May inclusive. You will also be able to access the Cinéma les Arcades and the Cinéma de la Plage.
Which screenings can I access with my "3 DAYS IN CANNES" badge?
From Thursday 17 May, with your badge, you will be able to access Official Selection screenings (Competition, Out of Competition, Special Screenings, Un Certain Regard, Cannes Classics, Cinéma de la plage).
the "3 DAYS IN CANNES" pass gives you the same access rights to Official Selection screenings as film industry badge-holders: Upon presentation of the badge – and subject to availability – to screenings in the Debussy, Buñuel and Soixantième Theatres. You will have the same access rights to screenings in the Grand Théâtre Lumière , i.e. by invitation only, and with just a small number of invitations available.
screenings have been specially reserved for you on 17 and 18 May, upon presentation of the "3 DAYS IN CANNES" badge, and subject to availability.
Saturday 19 May 2018, upon presentation of your badge.
Just like all festival-goers, the dress code is smart for all screenings, and evening wear is required for gala screenings (7:00 pm and 10:00 pm) at the Grand Théâtre Lumière!


text:
Japanese migrants and their descendants
Nikkei Chronicles
Nima-kai Traditions
Discover Nikkei Programs
Taiko Groups
Military Experience Database
What is Nikkei?
Vince Ota
Being a Japanese American in Japan
Japanese American Creative designer living in Japan
Little contact with Asians growing up on the east coast Spending summers in Los Angeles Japanese Americans brought up to deny their roots Being multicultural before it was "in" Moving to and living in Japan The reason to stay in Japan after his third year Being a Japanese American in Japan Never being Japanese Japan as my home Different tension between East Coast and Los Angeles A stereotype of Japanese Americans Main differences between Japanese and Japanese Americans
Transcripts available in the following languages:
Being a Japanese American in Japan, and coming here as a Japanese American, I think it made it more difficult when I first got here. I think it's kind of gone in phases. It was difficult at first because there's a lot of expectation. People meet you and they expect you to speak Japanese. "You look Japanese, why don't you speak Japanese?" And I guess part of that's my fault because I didn't learn Japanese until I got here. But, there's just expectation in terms of behavior as well. I learned this inside the school when I was working at the university. Japanese business structure, or the hierarchies that they have established are very clear, and behaviors associated with those structures are very clear. And I have never been one to conform, but it just kind of gave me a new point of view on things. Being a foreigner in this country, I kind of had to make my way in and learn that. But, yeah, I think it made it difficult.
Then as I began to learn more Japanese, it made it easier in some ways. Again, I'll go back to the American thing. It makes it easier to for me to disassociate myself from very rude, brash, obviously American people that are behaving badly because of culture shock or for whatever reason. Called being a "stealth gaijin." You can move in and out of the crowd sometimes. But, in terms of my relationships with other Japanese people, it made it easier just because—on the second phase—it made it easier just because there's not that tension. They're not meeting this obviously gaijin or foreign person. They're meeting someone they can look at and deal with an not have that extra level of tension there.
And I guess in the third phase, it's gotten difficult again because my American sensibilities, in terms of being an individual and doing things my way, have started to get in the way again. So I know how the Japanese system works, and I know how the Japanese people think and work—not everything, but for the most part. But, at same time, now I'm at a point now—I acquiesced in the beginning. I learned about it, and then I found the things that I don't like about the society or interaction and relationships and how people are. And now, I've made conscious decisions in those terms. So now, things have gotten, again, a little bit difficult.
FindingHome gaijin Japan
Related Interviews
Visiting Japan to study kendo
Peter Mizuki
Why I'm glad I immigrated to America (Japanese)
Jean Hamako Schneider
The reason why he immigrated to Japan (Portuguese)
Antonio Shinkiti Shikota
Appreciation of Japanese food
My image of America as a child (Japanese)
Edward Toru Horikiri
More interviews »
How to Conduct Your Own Interview
This guide will give you the fundamental knowledge you will need to conduct your own oral history interview.
February 7 • 5 p.m. (PST) |
7 p.m. (Mexico City)
Featured Nima: Sergio Hernández Galindo
Guest Host: Alberto Matsumoto
[Language: Spanish]
Support this project
Discover Nikkei is a place to connect with others and share the Nikkei experience. To continue to sustain and grow this project, we need your help!
Ways to help >>
A project of the
Major support by


text:
Sympherobius pygmaeus är en insektsart som först beskrevs av Jules Pièrre Rambur 1842.  Sympherobius pygmaeus ingår i släktet Sympherobius, och familjen florsländor. Enligt den finländska rödlistan är arten nära hotad i Finland. Arten är reproducerande i Sverige. Artens livsmiljö är lundskogar. Inga underarter finns listade.

Källor

Florsländor
pygmaeus